Structure-based, C2 symmetric inhibitors of HIV protease.

作者信息

Kempf D J, Norbeck D W, Codacovi L, Wang X C, Kohlbrenner W E, Wideburg N E, Paul D A, Knigge M F, Vasavanonda S, Craig-Kennard A

机构信息

Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064.

出版信息

J Med Chem. 1990 Oct;33(10):2687-9. doi: 10.1021/jm00172a002.

DOI:10.1021/jm00172a002

PMID:2213822

Abstract

摘要

相似文献

Structure-based, C2 symmetric inhibitors of HIV protease.

J Med Chem. 1990 Oct;33(10):2687-9. doi: 10.1021/jm00172a002.

Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR.

J Med Chem. 1994 Jun 10;37(12):1758-68. doi: 10.1021/jm00038a005.

Potential renin inhibitors. 2. Ethanolamine and ethylamine derivatives of phospholipids.潜在的肾素抑制剂。2. 磷脂的乙醇胺和乙胺衍生物。

J Med Chem. 1972 Jan;15(1):58-60. doi: 10.1021/jm00271a015.

Reduced-bond tight-binding inhibitors of HIV-1 protease. Fine tuning of the enzyme subsite specificity.

FEBS Lett. 1992 Feb 17;298(1):9-13. doi: 10.1016/0014-5793(92)80010-e.

Concise and stereocontrolled synthesis of pseudo-C2-symmetric diamino alcohols and triamines for use in HIV protease inhibitors.用于HIV蛋白酶抑制剂的拟C2对称二氨基醇和三胺的简洁且立体可控的合成。

J Org Chem. 2003 Feb 21;68(4):1418-25. doi: 10.1021/jo026616j.

Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol.基于对称性的HIV蛋白酶抑制剂。酰化的2,4-二氨基-1,5-二苯基-3-羟基戊烷和2,5-二氨基-1,6-二苯基己烷-3,4-二醇的构效关系研究。

J Med Chem. 1993 Feb 5;36(3):320-30. doi: 10.1021/jm00055a003.

A rational approach in the search for potent inhibitors against HIV proteinase.寻找抗HIV蛋白酶有效抑制剂的合理方法。

FASEB J. 1991 Aug;5(11):2606-10. doi: 10.1096/fasebj.5.11.1868985.

Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors.深入了解 HIV 蛋白酶与分泌型天冬氨酸蛋白酶-2 的结构相似性及 HIV-白念珠菌抑制剂的结合模式分析。

J Enzyme Inhib Med Chem. 2013 Oct;28(5):936-43. doi: 10.3109/14756366.2012.696245. Epub 2012 Jul 18.

Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.猫免疫缺陷病毒（FIV）蛋白酶S3和S3'亚位点特异性分析：一种对FIV、SIV和HIV在体外和体内均有效的广谱蛋白酶抑制剂的研发。

Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):939-44. doi: 10.1073/pnas.95.3.939.

A symmetric inhibitor binds HIV-1 protease asymmetrically.一种对称抑制剂以不对称方式结合HIV-1蛋白酶。

Biochemistry. 1993 Jan 26;32(3):937-47. doi: 10.1021/bi00054a027.

引用本文的文献

Ritonavir's Evolving Role: A Journey from Antiretroviral Therapy to Broader Medical Applications.利托那韦的演进角色：从抗逆转录病毒疗法到更广泛的医学应用。

Curr Oncol. 2024 Oct 8;31(10):6032-6049. doi: 10.3390/curroncol31100450.

Asymmetric dihydroxylation route to a dipeptide isostere of a protease inhibitor: enantioselective synthesis of the core unit of ritonavir.一种蛋白酶抑制剂二肽类似物的不对称二羟基化合成路线：利托那韦核心单元的对映选择性合成。

Chem Commun (Camb). 1999;1999(11):1025-1026. doi: 10.1039/A902518I.

STEREOCONTROLLED SYNTHESIS OF HIV-l PROTEASE INHIBITORS WITH C-AXIS OF SYMMETRY.具有C对称轴的HIV-1蛋白酶抑制剂的立体控制合成。

Tetrahedron Lett. 1991 Oct 7;32(41):5729-5732. doi: 10.1016/S0040-4039(00)93541-X. Epub 2001 Mar 26.

Potent HIV-1 Protease Inhibitors: Stereoselective Synthesis of a Dipeptide Mimic.强效HIV-1蛋白酶抑制剂：二肽模拟物的立体选择性合成

J Org Chem. 1993 Feb;58(5):1025-1029. doi: 10.1021/jo00057a011.

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.利托那韦。临床药代动力学及与其他抗HIV药物的相互作用。

Clin Pharmacokinet. 1998 Oct;35(4):275-91. doi: 10.2165/00003088-199835040-00002.

Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs.1型人类免疫缺陷病毒蛋白酶对对称环脲抑制剂类似物的抗性

Antimicrob Agents Chemother. 1997 Nov;41(11):2383-8. doi: 10.1128/AAC.41.11.2383.

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects.利托那韦在人类免疫缺陷病毒感染受试者中的多剂量药代动力学。

Antimicrob Agents Chemother. 1997 May;41(5):898-905. doi: 10.1128/AAC.41.5.898.

Synergistic binding of inhibitors to the protease from HIV type 1.抑制剂与1型人类免疫缺陷病毒蛋白酶的协同结合。

Biochem J. 1996 Apr 1;315 ( Pt 1)(Pt 1):113-7. doi: 10.1042/bj3150113.

Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro.持续输注人免疫缺陷病毒1型（HIV-1）蛋白酶抑制剂A-77003在体外限制急性HIV-1感染中的疗效。

Antimicrob Agents Chemother. 1995 Nov;39(11):2523-7. doi: 10.1128/AAC.39.11.2523.

Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.人类免疫缺陷病毒1型蛋白酶的部分抑制会导致异常的病毒组装和非感染性颗粒的形成。

J Virol. 1993 Jul;67(7):4050-5. doi: 10.1128/JVI.67.7.4050-4055.1993.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验